Leo sent me an email , not just an email but a word doc.I have attached it below.He took a lot of time out of his busy schedule for this.
What disturbs me is that he has to refer to the emails he is getting regarding an "expected" Prurisol PR and that he has to remind people that they are being as "transparent" and upfront as possible.
This indicates to me that there are some "not so nice" people who are abusing the generosity of Mr.Ehrlich and possibly causing him to even get a little "defensive".
I personally am disgusted by this and although it is out of my control,I will watch to find out who may be responsible for this behavior.If I find out who,I will plaster it over ihe internet.I believe I also have a number of "associates" who will assist me in this.
I will also make sure that I will not share anymore info on this board.I will only share with those I know , trust,and have some "class".Leo has been our "BEST FRIEND".DON'T F..K it up.As Dr.Banner (The Hulk)says "You won't like me when I'm angry".DON'T DESTROY OPEN COMMUNICATIONS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Kelt (See Below)
Hi Jim,
It’s true we are very busy now, but I felt it important to get back to you and answer your question.
Post 3614 by DrFeelgood is a very good estimation of the phase 1 study. Regarding Post 3618, it’s not that the patient has 3 months to live, but has at least 3 months to live.
Some additional points. I hope they’ll help you better understand our phase 1 trial.
Cellceutix will be starting a Phase 1 trial in which Kevetrin will be given as an intravenous infusion to cancer patients. Kevetrin will be given in increasing doses to determine the maximum dose that can be given based on safety endpoints, according to standard NCI and NIH guidelines. Kevetrin will be given as a 1 hour infusion to a cohort of 3 patients once weekly for 3 weeks with a 1 week rest period (1 cycle). The dose will be increased for each cohort of patients, as long as the side effects are acceptable. Patients are expected to receive at least 2 cycles of drug; however, if patients respond they may continue treatment indefinitely. Once the highest dose is reached that is well-tolerated, a Phase 2 trial can then begin.
Regarding Prurisol, the other topic in my email, I have been getting emails that people are expecting a press release. ????????????
I had previously written you…
“It is important that when considering a strategy for Prurisol take into account that management interests are aligned with stockholders. Dr Menon and I are large stockholders of CTIX. At this time when the stock is trading at this level a major dilution is not a serious consideration. We need a little more time and will release our plan which we believe will be in the best interests of our shareholders and possibly generate significant value to CTIX.”
As you know when we had the IND declined by the FDA because of Formatech, we moved aggressively on remanufacturing the product, and preparing the documentation for a 505(b)2 on Prurisol. In addition we starting working with the hospital IRB and SRC. I believe this is very unusual that we accomplished getting the hospital approval and FDA approval on the same day.
You have to trust that we are not asleep at the wheel and we are working hard on our plan to get Prurisol into a human study ASAP.
When we finalize that plan, only then will we will issue a press release. And I reiterate … “will release our plan which we believe will be in the best interests of our shareholders and possibly generate significant value to CTIX.”
Leo Ehrlich
